Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI SecuritiesMoneycontrol • about 17 hours ago
Net Sales are expected to decrease by 4.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs 6,290.9 crore, according to ICICI Securities.
Share to Feed
Breach of 22,500-22,450 levels may trigger further profit booking, potentially towards 22,300 and beyond in the near term.
After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits
While most of the corporates have shown double digit value growth, unit growth remains a challenge for the Indian pharma market, according to analysts
Cipla's Patalganga plant manufactures active pharmaceutical ingredients (APIs), the key raw materials for medicines, as well as formulations.
Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1700 in its research report dated March 14, 2024.
Investigations revealed that Nectar Herbs and Drugs based in Uttarakhand was manufacturing and distributing counterfeit drugs. Brands such as GSK, Alkem, Aristo, and Cipla were among those exploited by the firm. Counterfeit versions of popular medications like Augmentin 625, Calvum-625, Omnicef-O 200, and Montclair LC were being produced at the illicit facility.
Investigations revealed that Nectar Herbs and Drugs based in Uttarakhand was manufacturing and distributing counterfeit drugs. Brands such as GSK, Alkem, Aristo, and Cipla were among those exploited by the firm. Counterfeit versions of popular medications like Augmentin 625, Calvum-625, Omnicef-O 200, and Montclair LC were being produced at the illicit facility.
Investigations revealed that Nectar Herbs and Drugs based in Uttarakhand was manufacturing and distributing counterfeit drugs. Brands such as GSK, Alkem, Aristo, and Cipla were among those exploited by the firm. Counterfeit versions of popular medications like Augmentin 625, Calvum-625, Omnicef-O 200, and Montclair LC were being produced at the illicit facility.